After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Bicara Therapeutics Inc is $824.47M. A total of 0.55 million shares were traded on the day, compared to an average of 576.48K shares.
In the most recent transaction, Cohlhepp Ryan sold 12,500 shares of BCAX for 18.16 per share on Oct 15 ’25. After the transaction, the President and COO now owns 198,141 company shares. In a previous transaction on Oct 16 ’25, Mazumdar Claire bought 24,103 shares at 18.83 per share.
Among the insiders who sold shares, Mazumdar Claire disposed of 13,289 shares on Oct 15 ’25 at a per-share price of $18.84. This resulted in the Chief Executive Officer holding 309,892 shares of BCAX after the transaction. In another insider transaction, Mazumdar Claire sold 11,445 shares at $18.92 per share on Oct 13 ’25. Company shares held by the Chief Executive Officer now total 309,892.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BCAX has a high of $24.09 and a low of $7.80.
As of this writing, BCAX has an earnings estimate of -$0.67 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.57 per share and a lower estimate of -$0.73. The company reported an EPS of -$0.39 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCAX is Buy with a score of 4.60.
